What is the core deal between Memphasys and TK Biotech?

Memphasys (ASX:MEM) executed an exclusive commercialisation agreement with distributor TK Biotech to sell and market its Felix system in Poland.

What are the financial details of the Memphasys agreement?

Memphasys (ASX:MEM) secured a two-year contract with a minimum guaranteed value of $350,000.

How does the Memphasys rollout structure work over time?

Memphasys (ASX:MEM) will start with an initial three-month evaluation and market-introduction period before mandatory quarterly purchase commitments commence.

What market conditions in Poland are driving the strategy for Memphasys?

Memphasys (ASX:MEM) stated that it is targeting Poland because the government's publicly funded IVF program expands treatment access across 58 fertility clinics.

How does Poland fit into the broader European expansion for Memphasys?

Memphasys (ASX:MEM) added Poland as its third European market following CE Mark approval, expanding its footprint alongside existing commercial agreements in Italy and the United Kingdom.

Health

Image for illustrative purposes only. Not a real photo.

Memphasys signs $350,000 commercial agreement in Poland

Written by Mahathir BayenaPublished Aug 5, 2026, 5:15 AM

Memphasys executed an exclusive agreement with TK Biotech to commercialise the Felix system in Poland.
The two-year contract secures a minimum value of $350,000 following an initial three-month evaluation.
The company stated the transaction leverages Poland's publicly funded IVF programme to advance its European rollout.

Medical device developer Memphasys (ASX:MEM) executed an exclusive $350,000 commercialisation agreement with TK Biotech in Poland.

The transaction expands the company's regional footprint beyond Italy and the United Kingdom following CE Mark approval.

The commercial framework incorporates a three-month evaluation period before transitioning into mandatory quarterly purchase commitments.

The company stated the Polish market registered 51,000 qualified couples and 29,806 clinical pregnancies as of May.

Following the announcement, the Memphasys share price was unchanged at $0.0070 as the business pursues further European expansion.

The distributor will coordinate product demonstrations and facilitate customer training for fertility clinics following initial market introduction.

The broader commercial strategy focuses on establishing recurring revenue pathways through regional partnerships with established clinical distributors.

Memphasys signs $350,000 commercial agreement in Poland

Perguntas frequentes

Ativos relacionados a notícia